SLC6A19 and phenylketonuria: Here, we demonstrate for what is, to our knowledge, the first time that pharmacological inhibition of SLC6A19 increases the urinary excretion of neutral amino acids, including Phe, and reduces plasma Phe levels in a mouse model of PKU.